XML 26 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Investments in Real Estate
12 Months Ended
Dec. 31, 2019
Investments in Real Estate  
Investments in Real Estate

6. Investments in Real Estate

The Company acquired the following properties during the year ended December 31, 2019 (dollars in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rentable 

 

Initial

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Square

 

 Purchase

 

Transaction

 

 

 

 

Property

    

Market

    

Closing Date

    

Feet(1)

    

 Price

    

 Costs

    

Total

 

Sacramento CA

 

California

 

 

February 8, 2019

 

 

43,000

 

$

6,664

 

$

35

 

$

6,699

(2)

PharmaCann OH

 

Ohio

 

 

March 13, 2019

 

 

58,000

 

 

700

 

 

11

 

 

711

(3)

Southern CA Portfolio

 

California

 

 

April 16, 2019

 

 

102,000

 

 

27,097

 

 

51

 

 

27,148

  

Maitri PA

 

Pennsylvania

 

 

April 24, 2019

 

 

51,000

 

 

6,250

 

 

234

 

 

6,484

(4)

Vireo OH

 

Ohio

 

 

May 14, 2019

 

 

11,000

 

 

1,018

 

 

18

 

 

1,036

(5)

Green Leaf PA

 

Pennsylvania

 

 

May 20, 2019

 

 

266,000

 

 

13,000

 

 

207

 

 

13,207

  

Emerald Growth MI

 

Michigan

 

 

June 7, 2019

 

 

45,000

 

 

6,860

 

 

18

 

 

6,878

(6)

Ascend MI

 

Michigan

 

 

July 2, 2019

 

 

145,000

 

 

4,750

 

 

18

 

 

4,768

(7)

MJardin NV

 

Nevada

 

 

July 12, 2019

 

 

43,000

 

 

3,830

 

 

26

 

 

3,856

(8)

DYME CA

 

California

 

 

July 23, 2019

 

 

35,000

 

 

13,000

 

 

19

 

 

13,019

(9)

Trulieve MA

 

Massachusetts

 

 

July 26, 2019

 

 

150,000

 

 

3,500

 

 

25

 

 

3,525

(10)

PharmaCann PA

 

Pennsylvania

 

 

August 9, 2019

 

 

54,000

 

 

942

 

 

12

 

 

954

(11)

Vertical CA Portfolio

 

California

 

 

Various

 

 

79,000

 

 

17,300

 

 

32

 

 

17,332

(12)

The Pharm AZ - Retail

 

Arizona

 

 

September 19, 2019

 

 

2,000

 

 

2,000

 

 

27

 

 

2,027

(13)

LivWell MI

 

Michigan

 

 

October 9, 2019

 

 

156,000

 

 

19,000

 

 

28

 

 

19,028

(14)

Cresco IL Portfolio

 

Illinois

 

 

October 22, 2019

 

 

90,000

 

 

32,800

 

 

16

 

 

32,816

(15)

Trulieve FL

 

Florida

 

 

October 23, 2019

 

 

120,000

 

 

17,000

 

 

 4

 

 

17,004

  

Green Peak MI – Retail Portfolio

 

Michigan

 

 

Various

 

 

31,000

 

 

10,042

 

 

32

 

 

10,074

(16)

PharmaCann IL

 

Illinois

 

 

October 30, 2019

 

 

66,000

 

 

18,000

 

 

 8

 

 

18,008

(17)

Grassroots IL

 

Illinois

 

 

October 30, 2019

 

 

120,000

 

 

10,500

 

 

41

 

 

10,541

(18)

GTI PA

 

Pennsylvania

 

 

November 12, 2019

 

 

148,000

 

 

20,300

 

 

233

 

 

20,533

(19)

Grassroots ND

 

North Dakota

 

 

December 20, 2019

 

 

33,000

 

 

9,910

 

 

24

 

 

9,934

(20)

Grassroots PA

 

Pennsylvania

 

 

December 20, 2019

 

 

72,000

 

 

14,220

 

 

87

 

 

14,307

(21)

Total

 

 

 

 

 

 

 

1,920,000

 

$

258,683

 

$

1,206

 

$

259,889

(22)


(1)

Includes expected rentable square feet at completion of construction of certain properties.

(2)

The seller of the property is expected to complete redevelopment of the property, for which we have agreed to provide reimbursement of up to approximately $4.8 million as additional purchase price. As of December 31, 2019, we incurred and funded the entire additional purchase price.

(3)

Concurrent with the closing, we entered into a long-term lease and development agreement with a subsidiary of PharmaCann, which is expected to construct two buildings at the property, for which we have agreed to provide reimbursement of up to $19.3 million. As of December 31, 2019, we incurred approximately $16.0 million of the development costs, of which we funded approximately $15.4 million.

(4)

The tenant is expected to complete redevelopment of the property for which we have agreed to provide reimbursement of up to $10.0 million. As of December 31, 2019, we incurred approximately $6.0 million of the redevelopment costs, of which we funded approximately $4.5 million.

(5)

The tenant is expected to complete redevelopment of the property for which we have agreed to provide reimbursement of up to approximately $2.6 million. As of December 31, 2019, we incurred and funded approximately $2.5 million of the redevelopment costs.

(6)

The tenant is expected to complete redevelopment of the property for which we have agreed to provide reimbursement of up to approximately $3.1 million. As of December 31, 2019, we incurred approximately $3.1 million of the redevelopment costs, of which we funded approximately $2.9 million.

(7)

The tenant is expected to complete redevelopment of the property for which we have agreed to provide reimbursement of up to $15.0 million. As of December 31, 2019, we incurred approximately  $1.8 million of the redevelopment costs, of which no amount was funded.

(8)

The tenant is expected to complete redevelopment of the property for which we have agreed to provide reimbursement of up to approximately $5.8 million. As of December 31, 2019, we incurred approximately $4.1 million of the redevelopment costs, of which we funded approximately $3.5 million.

(9)

The tenant is expected to complete redevelopment of the property for which we have agreed to provide reimbursement of up to $2.0 million. As of December 31, 2019, no amount has been incurred. Subsequent to the end of the year, in January 2020, the tenant defaulted on its obligations to pay rent to us pursuant to our lease.

(10)

The tenant is expected to complete redevelopment of the property for which we have agreed to provide reimbursement of up to $40.0 million, which funding is subject to reduction at the tenant’s option until January 26, 2021. As of December 31, 2019, we have incurred approximately $4.3 million of the redevelopment costs, of which we funded approximately $2.6 million.

(11)

Concurrent with the closing, we entered into a long-term lease and development agreement with a subsidiary of PharmaCann, which is expected to construct two buildings at the property, for which we have agreed to provide reimbursement of up to $25.1 million. The construction funding may be increased by up to an additional $4.0 million at PharmaCann’s election within the first nine months of the lease term, subject to the satisfaction of certain conditions. Subsequent to the end of the year, in February 2020, this optional $4.0 million in construction funding was cancelled in its entirety. As of December 31, 2019, we incurred approximately $2.3 million of the development costs, of which we funded approximately $745,000.

(12)

Portfolio consists of four properties, with three properties closing on August 29, 2019 and the remaining property closing on September 11, 2019.

(13)

The tenant is expected to complete development of the property for which we have agreed to provide reimbursement of up to $500,000. As of December 31, 2019, we incurred $500,000 of the development costs, of which we funded approximately $452,000.

(14)

The tenant is expected to complete development of the property for which we have agreed to provide reimbursement of up to $23.0 million. As of December 31, 2019, we incurred approximately $9.0 million of the development costs, of which we funded approximately $6.6 million.

(15)

Portfolio consists of two properties. The tenant is expected to complete development of the properties for which we have agreed to provide reimbursement of up to approximately $13.8 million in the aggregate. As of December 31, 2019, we incurred approximately $9.6 million of the development costs, of which we funded approximately $2.7 million.

(16)

Portfolio consists of six properties closing between October 25, 2019 and November 25, 2019. The tenant is expected to complete development of one of the properties for which we have agreed to provide reimbursement of up to approximately $1.2 million. As of December 31, 2019, we have incurred approximately $312,000 of the development costs, of which no amount was funded.

(17)

Concurrent with the closing, we entered into a long-term lease and development agreement with a subsidiary of PharmaCann, which is expected complete the development of the property, for which we have agreed to provide reimbursement of up to $7.0 million. As of December 31, 2019, we have incurred approximately $321,000 of the development costs, of which no amount was funded.

(18)

The tenant is expected to complete redevelopment of the property for which we have agreed to provide reimbursement of up to approximately $17.7 million, which funding is subject to reduction at the tenant’s option within the first nine months of the lease term. As of December 31, 2019, we have incurred approximately $1.9 million of the redevelopment costs, of which we funded approximately $1.3 million.

(19)

The tenant is expected to complete redevelopment of the property for which we have agreed to provide reimbursement of up to $19.3 million. As of December 31, 2019, we incurred approximately $970,000, of which no amount was funded.

(20)

The tenant is expected to complete redevelopment of the property for which we have agreed to provide reimbursement of up to approximately $2.3 million . As of December 31, 2019, we incurred approximately $1.2 million, of which no amount was funded.

(21)

The tenant is expected to complete redevelopment of the property for which we have agreed to provide reimbursement of up to approximately $10.9 million . As of December 31, 2019, we incurred approximately $1.1 million, of which no amount was funded.

(22)

Approximately $28.2 million was allocated to land and approximately $231.7 million was allocated to buildings and improvements.

In addition, in June 2019, we amended our lease with Green Peak Industries, LLC (“Green Peak”) at one of our Michigan properties, making available an additional $18.0 million in funding for further expansion of cannabis cultivation and processing facilities at the property, increasing the total tenant improvement allowance to $25.5 million. As of December 31, 2019, we incurred and funded approximately $10.3 million of the redevelopment costs and our total investment in the property was approximately $15.8 million. Subsequent to December 31, 2019, in January 2020, we amended the lease with Green Peak which, among other things, canceled the remaining tenant improvement allowance of approximately $15.2 million and adjusted the corresponding base rent.

In September 2019, we amended our lease with a wholly owned subsidiary of Ascend Wellness Holdings, LLC at one of our Illinois properties, making available an additional $8.0 million in funding for further expansion of cannabis cultivation and processing facilities at the property. Assuming full payment of the additional funding, our total tenant improvement allowance will be $14.0 million and our total investment in the property will be $33.0 million. As of December 31, 2019, we incurred $14.0 million of the redevelopment costs, of which approximately $13.2 million was funded.

In September 2019, we amended our lease with Holistic Industries, Inc. at one of our Massachusetts properties, making available up to $2.0 million in reimbursement for tenant improvements at the property. As of December 31, 2019, the entire amount was incurred and funded.

In September 2019, we amended our lease and development agreement with a subsidiary of PharmaCann at one of our Massachusetts properties, making available an additional $8.0 million in construction funding for further development of cannabis cultivation and processing facilities at the property. Assuming full payment of the additional funding, our total construction funding will be $23.5 million and our total investment in the property will be $26.5 million. As of December 31, 2019, we incurred approximately $21.8 million of the redevelopment costs, of which $20.3 million was funded. Subsequent to December 31, 2019, in February 2020, we made available an additional $4.0 million in construction funding commitment for further development of the property.

In September 2019, we amended our lease with a subsidiary of Vireo Health, Inc. at our Minnesota property, making available an additional $2.6 million in reimbursement for tenant improvements at the property. Assuming full payment of the additional funding, our total tenant improvements will be approximately $5.6 million and our total investment in the property will be $8.6 million. As of December 31, 2019, we incurred approximately $5.2 million of the redevelopment costs, of which $4.4 million was funded.

Including all of our properties, during the year ended December 31, 2019, we capitalized costs of approximately $107.2 million and funded approximately $84.7 million relating to tenant improvements and construction activities at our properties.

The properties acquired during 2019 generated approximately $16.3 million of rental revenue (including tenant reimbursements) and approximately $12.5 million of net operating income after deducting property and depreciation expenses for the year ended December 31, 2019. The properties acquired during 2018 generated approximately $2.9 million of rental revenue (including tenant reimbursements) and approximately $2.2 million net operating income after deducting property and depreciation expenses for the year ended December 31, 2018.

Future contractual minimum rent (including base rent, supplemental base rent (with respect to our lease with PharmaCann at one of our New York properties) and property management fees) under the operating leases as of December 31, 2019 for future periods is summarized as follows (in thousands):

 

 

 

 

 

Year

    

Contractual Minimum Rent

2020

 

$

84,910

2021

 

 

89,750

2022

 

 

91,212

2023

 

 

93,979

2024

 

 

96,840

Thereafter

 

 

1,222,371

Total

 

$

1,679,062